Growth & profitability
- Revenue has grown 53.2% per year over the past 5 years.
Financial health
- Total debt ($118M) exceeds cash ($68M); net debt is $49M.
- Total debt has grown slower than revenue (-46.7% vs 53.2% per year).
13 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $143M | -$259M | 0.0% | 0.0% | — | $118M | $68M |
| 2024 | $92M | -$556M | 0.0% | 0.0% | — | $150M | $47M |
| 2023 | $51M | $5M | 0.0% | 0.0% | — | $508M | $19M |
| 2022 | $31M | $522M | 0.0% | 0.0% | — | $639M | $20M |
| 2021 | $26M | -$17M | 0.0% | 0.0% | — | $2.2B | $10M |
| 2020 | — | -$437M | — | — | — | $2.7B | $35M |
| 2019 | — | -$216M | — | — | — | $2.8B | $81M |
| 2018 | — | $186M | — | — | — | $2.9B | $83M |
| 2017 | — | -$329M | — | — | — | $992M | $625M |
| 2016 | — | $75M | — | — | — | — | $96M |
| 2012 | — | -$257M | — | — | — | $150M | — |
| 2011 | — | -$2.0B | — | — | — | $224M | — |
| 2010 | — | -$753M | — | — | — | $208M | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $68M | -$7M | 0.0% | 0.0% | — | $117M | $94M |
| Dec '25 | $40M | -$27M | 0.0% | 0.0% | — | $118M | $68M |
| Sep '25 | $36M | -$113M | 0.0% | 0.0% | — | — | $52M |
| Jun '25 | $30M | -$73M | 0.0% | 0.0% | — | — | $46M |
| Mar '25 | $37M | -$46M | 0.0% | 0.0% | — | — | $52M |
| Dec '24 | $38M | -$548M | 0.0% | 0.0% | — | $150M | $47M |
| Sep '24 | $23M | -$28M | 0.0% | 0.0% | — | $666M | $57M |
| Jun '24 | $13M | -$750000 | 0.0% | 0.0% | — | $515M | $25M |
| Mar '24 | $18M | $21M | 0.0% | 0.0% | — | $512M | $25M |
| Dec '23 | $12M | -$16M | 0.0% | 0.0% | — | $508M | $19M |
| Sep '23 | $15M | $66M | 0.0% | 0.0% | — | $505M | $302M |
| Jun '23 | $10M | -$13M | 0.0% | 0.0% | — | $501M | $309M |
| Mar '23 | $14M | -$33M | 0.0% | 0.0% | — | $497M | $304M |
| Dec '22 | $9M | $175M | 0.0% | 0.0% | — | $639M | $20M |
| Sep '22 | $7M | $340M | 0.0% | 0.0% | — | $2.2B | $38M |
| Jun '22 | $6M | $5M | 0.0% | 0.0% | — | $2.2B | $39M |
| Mar '22 | $9M | $2M | 0.0% | 0.0% | — | $2.2B | $116M |
| Dec '21 | — | -$22M | — | — | — | $2.2B | $10M |
| Sep '21 | $7M | $17M | 0.0% | 0.0% | — | $2.2B | $22M |
| Jun '21 | $6M | -$29M | 0.0% | 0.0% | — | $2.7B | $32M |
How the market has priced OSG against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, OCTAVE SPECIALTY GROUP INC's revenue has grown 53.2% per year. These are computed facts, not advice.
As of FY2025, OCTAVE SPECIALTY GROUP INC reported $118M of total debt against $68M of cash.
In FY2025, gross margin was —, operating margin —, and net margin -180.6%.
As of Jun '26, OCTAVE SPECIALTY GROUP INC traded at a price-to-earnings ratio of about 76.4× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.